David G. Maloney
M.D., Ph.D.
Medical Director, Cellular Immunotherapy
👥Biography 个人简介
David Maloney is a leader in CAR-T cell therapy for lymphoma who has led pivotal clinical trials establishing CD19 CAR-T as standard treatment for relapsed/refractory large B-cell lymphoma. His work at Fred Hutch has been instrumental in multiple CAR-T product approvals.
David Maloney是淋巴瘤CAR-T细胞治疗的领导者，领导了确立CD19 CAR-T作为复发/难治性大B细胞淋巴瘤标准治疗的关键临床试验。他在Fred Hutch的工作对多个CAR-T产品的批准起到了关键作用。
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Lymphoma CAR-T
Led trials establishing CAR-T for large B-cell lymphoma.
Real-World Evidence
Generated post-approval data informing clinical practice.
Representative Works 代表性著作
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
New England Journal of Medicine (2017)
ZUMA-1 trial leading to Yescarta approval.
📄Data Sources 数据来源
Last updated: 2026-03-05 | All information from publicly available academic sources
Related Experts 相关专家
Carl H. June
University of Pennsylvania
Michel Sadelain
Memorial Sloan Kettering Cancer Center
Crystal L. Mackall
Stanford University
Katy Rezvani
MD Anderson Cancer Center
关注 David G. Maloney 的研究动态
Follow David G. Maloney's research updates
留下邮箱，当我们发布与 David G. Maloney（Fred Hutchinson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment